Suppr超能文献

[对β-内酰胺类抗生素过敏患者的抗菌治疗建议]

[Recommendations of antimicrobial treatment in patients allergic to beta-lactam antibiotics].

作者信息

Barberán J, Mensa J, Fariñas C, Llinares P, Olaechea P, Palomar M, Torres Mj, Moreno E, Serrano R, García Ja

机构信息

Sociedad Española de Quimioterapia.

出版信息

Rev Esp Quimioter. 2008 Mar;21(1):60-82.

Abstract

Beta-lactam antibiotics are the cornerstone of most of the severe bacterial infections. However, their use can be limited by resistances and allergic reactions. Allergic reactions to beta-lactam antibiotics account for only a small proportion of reported adverse drug reactions, but they are related with an important morbidity, mortality and increase of the health care costs. Drug-specific IgE antibodies cause early reactions, whereas T cells play a predominant role in delayed hypersensitivity reactions. For penicillin a major antigenic determinant and several minor determinants have been identified. Clinical assessment is mandatory by medical history, skin and other testing, including provocation. If the beta-lactam should be avoided or a desensitization procedure should be performed depends on the nature and severity of the reaction. Several new antibiotics are currently available (tigecycline, linezolid, daptomycin, etc.) that are as effective and safe as beta-lactams. In this article we have developed a few recommendations for the management of patients with allergy to beta-lactams on the basis of evidence and expert opinion.

摘要

β-内酰胺类抗生素是大多数严重细菌感染治疗的基石。然而,其使用可能会受到耐药性和过敏反应的限制。β-内酰胺类抗生素引起的过敏反应在报告的药物不良反应中仅占一小部分,但它们与重要的发病率、死亡率以及医疗费用增加有关。药物特异性IgE抗体引起早期反应,而T细胞在迟发型超敏反应中起主要作用。对于青霉素,已经确定了主要抗原决定簇和几个次要决定簇。必须通过病史、皮肤及其他检测(包括激发试验)进行临床评估。是否应避免使用β-内酰胺类药物或进行脱敏程序取决于反应的性质和严重程度。目前有几种新型抗生素(替加环素、利奈唑胺、达托霉素等),它们与β-内酰胺类药物一样有效且安全。在本文中,我们根据证据和专家意见,针对对β-内酰胺类药物过敏的患者的管理提出了一些建议。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验